SAN FRANCISCO, March 2, 2021 — Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will present at the Barclays Global Healthcare Conference on March 10 and the H.C. Wainwright Global Life Sciences Conference on March 9-10. Dr. Richard Chin, Chief Executive Officer, will be available for one-on-one meetings. […]
/wp-content/uploads/2017/09/KindredBioHeader2017.png00Katja Buhrer/wp-content/uploads/2017/09/KindredBioHeader2017.pngKatja Buhrer2021-03-02 08:38:082021-03-02 08:38:10Kindred Biosciences to Present at Barclays Global Healthcare Conference and H.C. Wainwright Global Life Sciences Conference
San Francisco, California (February 25, 2021) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has submitted efficacy data to support the prophylactic indication for KIND-030 to the United States Department of Agriculture (USDA) Center for Veterinary Biologics for review. This submission […]
SAN FRANCISCO, February 16, 2021 — Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will present at the BofA Securities Animal Health Virtual Summit on February 25. Dr. Richard Chin, Chief Executive Officer, will present via webcast at 10.50am ET and be available for virtual one-on-one meetings. During this […]
/wp-content/uploads/2017/09/KindredBioHeader2017.png00Katja Buhrer/wp-content/uploads/2017/09/KindredBioHeader2017.pngKatja Buhrer2021-02-16 16:05:202021-02-16 16:05:21Kindred Biosciences to Present at the BofA Securities Animal Health Virtual Summit
San Francisco, California (February 9, 2021) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has appointed Lyndon Lien, Ph.D., an experienced biotech CEO, entrepreneur and investor, and Nanxi Liu, CEO and Co-Founder of Enplug and Co-Founder of Nanoly Bioscience, to its […]
/wp-content/uploads/2017/09/KindredBioHeader2017.png00Katja Buhrer/wp-content/uploads/2017/09/KindredBioHeader2017.pngKatja Buhrer2021-02-09 08:37:222021-02-09 08:37:23Kindred Biosciences Announces Two New Appointments to Board of Directors
San Francisco, California (December 22, 2020) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has initiated the pivotal efficacy study for tirnovetmab (KIND-016), a fully caninized, high-affinity monoclonal antibody targeting interleukin (IL)-31 for the treatment of atopic dermatitis in dogs. Atopic […]
-0.06 (-1.35%)
Kindred Biosciences to Present at Barclays Global Healthcare Conference and H.C. Wainwright Global Life Sciences Conference
/in Frontpage, Investor, News /by Katja BuhrerSAN FRANCISCO, March 2, 2021 — Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will present at the Barclays Global Healthcare Conference on March 10 and the H.C. Wainwright Global Life Sciences Conference on March 9-10. Dr. Richard Chin, Chief Executive Officer, will be available for one-on-one meetings. […]
Kindred Biosciences Announces Submission of Parvovirus Monoclonal Antibody Data for Prophylactic Indication
/in Frontpage, Investor, News /by Katja BuhrerSan Francisco, California (February 25, 2021) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has submitted efficacy data to support the prophylactic indication for KIND-030 to the United States Department of Agriculture (USDA) Center for Veterinary Biologics for review. This submission […]
Kindred Biosciences to Present at the BofA Securities Animal Health Virtual Summit
/in Frontpage, Investor, News /by Katja BuhrerSAN FRANCISCO, February 16, 2021 — Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will present at the BofA Securities Animal Health Virtual Summit on February 25. Dr. Richard Chin, Chief Executive Officer, will present via webcast at 10.50am ET and be available for virtual one-on-one meetings. During this […]
Kindred Biosciences Announces Two New Appointments to Board of Directors
/in Frontpage, Investor, News /by Katja BuhrerSan Francisco, California (February 9, 2021) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has appointed Lyndon Lien, Ph.D., an experienced biotech CEO, entrepreneur and investor, and Nanxi Liu, CEO and Co-Founder of Enplug and Co-Founder of Nanoly Bioscience, to its […]
Kindred Biosciences Initiates Pivotal Efficacy Study of Tirnovetmab (Interleukin-31) Monoclonal Antibody for Canine Atopic Dermatitis
/in Frontpage, Investor, News /by Katja BuhrerSan Francisco, California (December 22, 2020) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has initiated the pivotal efficacy study for tirnovetmab (KIND-016), a fully caninized, high-affinity monoclonal antibody targeting interleukin (IL)-31 for the treatment of atopic dermatitis in dogs. Atopic […]